NCT03512548View on ClinicalTrials.gov

Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 10, 2018

Primary Completion Date

July 29, 2019

Study Completion Date

August 23, 2019

Conditions
Healthy
Interventions
DRUG

Relacorilant 350mg

Relacorilant 350mg

DRUG

Itraconazole

Itraconazole 200 mg

DRUG

Relacorilant 300mg

Relacorilant 300mg

Trial Locations (1)

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY